Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations : Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E
PURPOSE: The National Cancer Institute Molecular Analysis for Therapy Choice trial is a signal-finding genomically driven platform trial that assigns patients with any advanced refractory solid tumor, lymphoma, or myeloma to targeted therapies on the basis of next-generation sequencing results. Subprotocol E evaluated osimertinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with EGFR mutations.
METHODS: Eligible patients had EGFR mutations (T790M or rare activating) and received osimertinib 80 mg once daily. Patients with lung cancer with EGFR T790M were excluded. The primary end point was objective response rate (ORR), and the secondary end points were 6-month progression-free survival (PFS), overall survival, and toxicity.
RESULTS: A total of 19 patients were enrolled: 17 were evaluable for toxicity and 13 for efficacy. The median age of the 13 included in the efficacy analysis was 63 years, 62% had Eastern Cooperative Oncology Group performance status 1, and 31% received >three previous systemic therapies. The most common tumor type was brain cancers (54%). The ORR was 15.4% (n = 2 of 13; 90% CI, 2.8 to 41.0) and 6-month PFS was 16.7% (90% CI, 0 to 34.4). The two confirmed RECIST responses were observed in a patient with neuroendocrine carcinoma not otherwise specified (EGFR exon 20 S768T and exon 18 G719C mutation) and a patient with low-grade epithelial carcinoma of the paranasal sinus (EGFR D770_N771insSVD). The most common (>20%) treatment-related adverse events were diarrhea, thrombocytopenia, and maculopapular rash.
CONCLUSION: In this pretreated cohort, osimertinib did not meet the prespecified end point threshold for efficacy, but responses were seen in a neuroendocrine carcinoma with an EGFR exon 20 S768T and exon 18 G719C mutation and an epithelial carcinoma with an EGFR D770_N771insSVD mutation. Osimertinib was well tolerated and had a safety profile consistent with previous studies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
JCO precision oncology - 8(2024) vom: 30. Apr., Seite e2300454 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chen, Monica F [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
3C06JJ0Z2O |
|---|
| Anmerkungen: |
Date Completed 10.04.2024 Date Revised 11.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1200/PO.23.00454 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370812158 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370812158 | ||
| 003 | DE-627 | ||
| 005 | 20240411232722.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240409s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/PO.23.00454 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1372.xml |
| 035 | |a (DE-627)NLM370812158 | ||
| 035 | |a (NLM)38591867 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chen, Monica F |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations |b Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.04.2024 | ||
| 500 | |a Date Revised 11.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a PURPOSE: The National Cancer Institute Molecular Analysis for Therapy Choice trial is a signal-finding genomically driven platform trial that assigns patients with any advanced refractory solid tumor, lymphoma, or myeloma to targeted therapies on the basis of next-generation sequencing results. Subprotocol E evaluated osimertinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with EGFR mutations | ||
| 520 | |a METHODS: Eligible patients had EGFR mutations (T790M or rare activating) and received osimertinib 80 mg once daily. Patients with lung cancer with EGFR T790M were excluded. The primary end point was objective response rate (ORR), and the secondary end points were 6-month progression-free survival (PFS), overall survival, and toxicity | ||
| 520 | |a RESULTS: A total of 19 patients were enrolled: 17 were evaluable for toxicity and 13 for efficacy. The median age of the 13 included in the efficacy analysis was 63 years, 62% had Eastern Cooperative Oncology Group performance status 1, and 31% received >three previous systemic therapies. The most common tumor type was brain cancers (54%). The ORR was 15.4% (n = 2 of 13; 90% CI, 2.8 to 41.0) and 6-month PFS was 16.7% (90% CI, 0 to 34.4). The two confirmed RECIST responses were observed in a patient with neuroendocrine carcinoma not otherwise specified (EGFR exon 20 S768T and exon 18 G719C mutation) and a patient with low-grade epithelial carcinoma of the paranasal sinus (EGFR D770_N771insSVD). The most common (>20%) treatment-related adverse events were diarrhea, thrombocytopenia, and maculopapular rash | ||
| 520 | |a CONCLUSION: In this pretreated cohort, osimertinib did not meet the prespecified end point threshold for efficacy, but responses were seen in a neuroendocrine carcinoma with an EGFR exon 20 S768T and exon 18 G719C mutation and an epithelial carcinoma with an EGFR D770_N771insSVD mutation. Osimertinib was well tolerated and had a safety profile consistent with previous studies | ||
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a osimertinib |2 NLM | |
| 650 | 7 | |a 3C06JJ0Z2O |2 NLM | |
| 650 | 7 | |a ErbB Receptors |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a Acrylamides |2 NLM | |
| 650 | 7 | |a Aniline Compounds |2 NLM | |
| 650 | 7 | |a Indoles |2 NLM | |
| 650 | 7 | |a Pyrimidines |2 NLM | |
| 700 | 1 | |a Song, Zihe |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Helena A |e verfasserin |4 aut | |
| 700 | 1 | |a Sequist, Lecia V |e verfasserin |4 aut | |
| 700 | 1 | |a Lovly, Christine M |e verfasserin |4 aut | |
| 700 | 1 | |a Mitchell, Edith P |e verfasserin |4 aut | |
| 700 | 1 | |a Moscow, Jeffrey A |e verfasserin |4 aut | |
| 700 | 1 | |a Gray, Robert J |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Victoria |e verfasserin |4 aut | |
| 700 | 1 | |a McShane, Lisa M |e verfasserin |4 aut | |
| 700 | 1 | |a Rubinstein, Larry V |e verfasserin |4 aut | |
| 700 | 1 | |a Patton, David R |e verfasserin |4 aut | |
| 700 | 1 | |a Williams, P Mickey |e verfasserin |4 aut | |
| 700 | 1 | |a Hamilton, Stanley R |e verfasserin |4 aut | |
| 700 | 1 | |a Umemura, Yoshie |e verfasserin |4 aut | |
| 700 | 1 | |a Tricoli, James V |e verfasserin |4 aut | |
| 700 | 1 | |a Conley, Barbara A |e verfasserin |4 aut | |
| 700 | 1 | |a Arteaga, Carlos L |e verfasserin |4 aut | |
| 700 | 1 | |a Harris, Lyndsay N |e verfasserin |4 aut | |
| 700 | 1 | |a O'Dwyer, Peter J |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Alice P |e verfasserin |4 aut | |
| 700 | 1 | |a Flaherty, Keith T |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JCO precision oncology |d 2017 |g 8(2024) vom: 30. Apr., Seite e2300454 |w (DE-627)NLM273576054 |x 2473-4284 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2024 |g day:30 |g month:04 |g pages:e2300454 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1200/PO.23.00454 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2024 |b 30 |c 04 |h e2300454 | ||